000			04750nam a22008057a 4500
008			200103s20192019 xxu||||| |||| 00| 0 eng d
022			_a1878-0938
024			_a10.1016/j.carrev.2019.09.022 [doi]
024			_aS1553-8389(19)30647-5 [pii]
040			_aOvid MEDLINE(R)
099			_a31870527
245			_aSafety and Feasibility of Performing Pericardiocentesis on Patients with Significant Pulmonary Hypertension.
251			_aCardiovascular Revascularization Medicine. 20(12):1090-1095, 2019 Dec.
252			_aCardiovasc Revasc Med. 20(12):1090-1095, 2019 Dec.
252			_zCardiovasc Revasc Med. 20(12):1090-1095, 2019 Dec.
253			_aCardiovascular revascularization medicine : including molecular interventions
260			_c2019
260			_fFY2020
265			_sppublish
266			_d2020-01-03
268			_aCardiovascular Revascularization Medicine. 20(12):1090-1095, 2019 Dec.
501			_aAvailable in print through MWHC library: 2002 - present
520			_aBACKGROUND/PURPOSE: Pericardial effusion (PE) is a complication of pulmonary hypertension (PHT) and, specifically, pulmonary arterial hypertension (PAH), that confers a worse prognosis. The safety of performing pericardiocentesis in patients with PHT has not been established. We aimed to assess the safety and feasibility of performing pericardiocentesis in patients with significant PHT.
520			_aCONCLUSIONS: Pericardiocentesis is a safe procedure, including in patients with significant PHT, including those with WHO Group I PAH. We advocate the use of invasive hemodynamic monitoring in patients with significant PHT.
520			_aMETHODS/MATERIALS: We performed a retrospective analysis from August 2013 to December 2018 at our tertiary-care center of patients who underwent a pericardiocentesis procedure. Patients, procedure, echocardiographic findings, any major intraprocedural complications, and post-procedural related complications up to 30days were recorded. Specifically, we studied patients with significant PHT.
520			_aRESULTS: The cohort included 170 patients, with an average age of 62.6years and an even distribution of gender and co-morbidities. The etiology for the PE varied. Major complications were rare (1.7%) and only 10 patients (5.9%) required re-intervention for reaccumulation of fluid. There were 27 patients (15.9%) with significant PHT, 5 with World Health Organization (WHO) Group I PAH (2.94%). In the entire cohort, there were only 3 major complications (1.7%), none among PHT patients.
520			_aSUMMARY: Pericardiocentesis tends to be a safe procedure. However, the safety of performing pericardiocentesis in patients with significant pulmonary hypertension has not been well established. We aimed to assess the safety and feasibility of performing pericardiocentesis, and specifically in patients with significant PHT out our tertiary center by performing a retrospective analysis. Copyright (c) 2019 Elsevier Inc. All rights reserved.
546			_aEnglish
650			_a*Pericardial Effusion/su [Surgery]
650			_a*Pericardiocentesis
650			_a*Pulmonary Arterial Hypertension/co [Complications]
650			_aAdult
650			_aAged
650			_aAged, 80 and over
650			_aFeasibility Studies
650			_aFemale
650			_aHemodynamics
650			_aHumans
650			_aMale
650			_aMiddle Aged
650			_aPatient Safety
650			_aPericardial Effusion/dg [Diagnostic Imaging]
650			_aPericardial Effusion/et [Etiology]
650			_aPericardial Effusion/pp [Physiopathology]
650			_aPericardiocentesis/ae [Adverse Effects]
650			_aPulmonary Arterial Hypertension/dg [Diagnostic Imaging]
650			_aPulmonary Arterial Hypertension/pp [Physiopathology]
650			_aRetrospective Studies
650			_aRisk Assessment
650			_aRisk Factors
650			_aSeverity of Illness Index
650			_aTreatment Outcome
650			_aVentricular Function, Right
651			_aMedStar Heart & Vascular Institute
657			_aJournal Article
700			_aBen-Dor, Itsik
700			_aCase, Brian C
700			_aForrestal, Brian J
700			_aHashim, Hayder
700			_aKagan, Calvin M
700			_aMedvedofsky, Diego
700			_aSatler, Lowell F
700			_aTariq, Muhammad U
700			_aWaksman, Ron
700			_aYang, Michael
700			_aYerasi, Charan
790			_aBen-Dor I, Case BC, Forrestal BJ, Hashim H, Kagan CM, Medvedofsky D, Rogers T, Satler LF, Tariq MU, Waksman R, Yang M, Yerasi C
856			_uhttps://dx.doi.org/10.1016/j.carrev.2019.09.022 _zhttps://dx.doi.org/10.1016/j.carrev.2019.09.022
942			_cART _dArticle
999			_c4857 _d4857